Compare
Amneal Pharmaceuticals vs Merck & (AMRX vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amneal Pharmaceuticals (AMRX) returned +72.3% and Merck & (MRK) +73.9%; so far this year the figures are +59.8% and +39.4%.
Merck & is the larger company by market value, about 56.3 times the size of Amneal Pharmaceuticals.
On trailing earnings, AMRX trades at 41.1 times and MRK at 149.7 times.
Revenue grew +9.3% at AMRX and +4.9% at MRK over the last year.
AMRX pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| AMRX | MRK | |
|---|---|---|
| Price | $20.14 | $146.73 |
| 1-day | +3.55% | -0.14% |
| YTD | +59.84% | +39.40% |
| 1 year | +72.28% | +73.87% |
| 3 years | +417.74% | +42.66% |
| Market cap | $6.4B | $361.7B |
| P/E | 41.1 | 149.7 |
| P/S | 2.06 | 5.37 |
| P/B | 194.76 | 8.06 |
| Revenue growth | +9.30% | +4.90% |
| EPS growth | +4800.00% | -87.10% |
| Gross margin % | 39.3 | 71.8 |
| Net margin % | 5.0 | 3.6 |
| ROE % | 476.5 | 5.5 |
| Debt / equity | 77.83 | 1.20 |
| FCF yield % | 2.0 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 0.62 | 0.18 |
| RSI (14) | 50.8 | 51.3 |
| Technical rating |